Modality
Vaccine
MOA
CFTRmod
Target
TIGIT
Pathway
Checkpoint
BCC
Development Pipeline
Preclinical
Dec 2025
→ Jan 2025
PreclinicalCurrent
NCT06433688
2,352 pts·BCC
2025-12→2025-01·Terminated
2,352 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-01-151.2y agoInterim· BCC
Trial Timeline
2025Q2Q3Q4
Preclinical
Termina…
Catalysts
Interim
2025-01-15 · 1.2y ago
BCC
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06433688 | Preclinical | BCC | Terminated | 2352 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| LLY-4358 | Eli Lilly | Phase 3 | B7-H3 | |
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| Gelinaritide | AbbVie | Preclinical | FcRn | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| BNT-5232 | BioNTech | NDA/BLA | TIGIT | |
| Darafutibatinib | BioNTech | Preclinical | PRMT5 | |
| Miritinib | Neurocrine | Phase 3 | TIGIT | |
| UTH-9370 | United Therapeutics | NDA/BLA | TIGIT | |
| Ivotuximab | Madrigal Pharma | Phase 2 | CD123 |